Z
Zaid Taha
Researcher at Queen's University
Publications - 12
Citations - 132
Zaid Taha is an academic researcher from Queen's University. The author has contributed to research in topics: Medicine & Oncolytic virus. The author has an hindex of 1, co-authored 4 publications receiving 71 citations. Previous affiliations of Zaid Taha include Ottawa Hospital Research Institute.
Papers
More filters
Journal ArticleDOI
The Hippo Pathway: Immunity and Cancer.
TL;DR: The mechanisms by which Hippo signaling in pathogen-infected or neoplastic cells affects the activities of immune cells that respond to these threats are summarized and the proposed directions for future work are proposed.
Journal ArticleDOI
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
Marie-Ève Wedge,Victoria A. Jennings,Mathieu J.F. Crupi,Joanna Poutou,Taylor R Jamieson,Adrian Pelin,Giuseppe Pugliese,Christiano Tanese de Souza,Julia Petryk,Brian Laight,Meaghan Boileau,Zaid Taha,Nouf Alluqmani,Hayley Elizabeth McKay,Larissa A. Pikor,Sarwat T. Khan,Taha Azad,Reza Rezaei,Bradley Austin,Xiaohong He,David Mansfield,Elaine G Rose,Emily E.F. Brown,N. Crawford,Almohanad A. Alkayyal,Abera Surendran,Ragunath Singaravelu,Dominic G. Roy,Gemma Migneco,Benjamin McSweeney,Mary Lynn Cottee,Egon J. Jacobus,Brian A. Keller,Takafumi N. Yamaguchi,Paul C. Boutros,Michele Geoffrion,Katey J. Rayner,Avijit Chatterjee,Rebecca C. Auer,Jean-Simon Diallo,Derrick Gibbings,Benjamin R. tenOever,Alan Melcher,John C. Bell,Carolina S. Ilkow +44 more
TL;DR: In this article , the authors performed an in-vitro screen based on virus-encoded artificial microRNAs (amiRNAs) and found that a unique amiRNA, termed amiR-4, confers a replicative advantage to the VSVΔ51 OV platform.
Journal ArticleDOI
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
Mathieu J.F. Crupi,Zaid Taha,T.J.A. Janssen,Julia Petryk,Stephen Boulton,Nouf Alluqmani,Anna Jirovec,Omar Kassas,Sarwat T. Khan,Sydney Vallati,Emily Lee,Ben Huang,Michael S. Huh,Larissa A. Pikor,Xiaohong He,Ricardo Marius,Bradley Austin,Jessie Duong,Adrian Pelin,Serge Neault,Taha Azad,Caroline J. Breitbach,David F. Stojdl,Michael A. Burgess,Scott McComb,Rebecca C. Auer,Jean-Simon Diallo,Carolina S. Ilkow,John C. Bell +28 more
TL;DR: In this article , the authors proposed a novel combination strategy for colorectal cancers using oncolytic vaccinia virus to enhance immune-payload delivery and boost T cell responses within tumours.
Journal ArticleDOI
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
Zaid Taha,Rozanne Arulanandam,Glib Maznyi,Elena Godbout,Madalina E. Carter-Timofte,Naziia Kurmasheva,Line S. Reinert,Andrew Chen,Mathieu J.F. Crupi,Stephen Boulton,Geneviève Laroche,Alexandra Phan,Reza Rezaei,Nouf Alluqmani,Anna Jirovec,Alexandra Acal,Emily E.F. Brown,Ragunath Singaravelu,Julia Petryk,Manja Idorn,Kyle Potts,Hayley Todesco,Cini Mathew John,Douglas J. Mahoney,Carolina S. Ilkow,Patrick M. Giguère,Tommy Alain,Marceline Côté,Søren R. Paludan,David Olagnier,John C. Bell,Taha Azad,Jean-Simon Diallo +32 more
TL;DR: In this article , a split nanoluciferase complementation assay was used to rapidly screen for inhibitors that interfere with binding of the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein with its target receptor, angiotensin-converting enzyme 2 (ACE2).
Journal ArticleDOI
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
Nouf Alluqmani,Anna Jirovec,Zaid Taha,Oliver Varette,Andrew Chen,Daniel Serrano,Glib Maznyi,Sarwat T. Khan,Nicole E. Forbes,Rozanne Arulanandam,Rebecca C. Auer,Jean-Simon Diallo +11 more
TL;DR: In this paper , the authors investigated the systemic impact of vanadium-based compounds such as vanadyl sulfate (VS) and oncolytic vesicular stomatitis virus (VSVΔ51) combination therapy to understand the immunological mechanism of action leading to improved antitumor responses.